Peptide United

Research comparison

Tesamorelin vs Sermorelin

Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.

Tesamorelin

Egrifta · TH9507

Approved

Tesamorelin is a stabilized synthetic GHRH analog FDA-approved for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It stimulates pulsatile GH secretion while preserving natural feedback regulation. Research demonstrates significant visceral adipose tissue reduction, improved lipid profiles, and cognitive benefits, making it a key study compound for metabolic dysfunction.

Research Status

FDA Approved

Half-Life

~26 minutes

Molecular Formula

Molecular Weight

CAS Number

218949-48-5

Research Categories

Growth Hormone Axis, Fat Loss & Metabolic

Routes of Administration

Subcutaneous (SQ)
Sermorelin

GHRH(1-29) · GRF 1-29 NH2 · Geref

Approved

Sermorelin is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary to produce and secrete growth hormone in a pulsatile, physiologic manner. FDA-approved for GH deficiency in children, it is extensively researched in adults for body composition, sleep quality, and age-related GH decline.

Research Status

FDA Approved

Half-Life

10–20 minutes

Molecular Formula

C₁₄₉H₂₄₆N₄₄O₄₂S

Molecular Weight

3357.88 Da

CAS Number

86168-78-7

Research Categories

Growth Hormone Axis, Anti-Aging & Longevity

Routes of Administration

Subcutaneous (SQ)Intravenous (IV)

Full mechanism comparison

Mechanism of action, pharmacokinetics, and research findings comparison available on the Researcher plan.

Unlock full comparison →